Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.59 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.56 |
| ▸ | CTSL | P07711 | 5/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | ECE1 | P42892 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 2/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7270223 | 0.90 | PSMB1 (0.59) | ADORA3ADORA2AADORA2BADORA1PSMB1 | |
| SCHEMBL7384058 | 0.88 | PSMB1 (0.60) | ADORA3ADORA2AADORA2BADORA1PSMB1 | |
| SCHEMBL7417704 | 0.88 | PSMB1 (0.60) | ADORA3ADORA2AADORA2BADORA1PSMB1 | |
| SCHEMBL27327218 | 0.86 | PSMB1 (0.56) | ADORA3ADORA2AADORA2BADORA1PSMB1 | |
| SCHEMBL7420596 | 0.86 | PSMB1 (0.61) | ADORA3ADORA2AADORA2BADORA1PSMB1 | |
| SCHEMBL7279478 | 0.86 | ADORA3 (0.56) | ADORA3ADORA2AADORA2BADORA1PSMB1 | |
| SCHEMBL7418250 | 0.86 | PSMB1 (0.61) | ADORA3ADORA2AADORA2BADORA1PSMB1 | |
| SCHEMBL7412449 | 0.86 | PSMB1 (0.61) | ADORA3ADORA2AADORA2BADORA1PSMB1 | |
| SCHEMBL7320613 | 0.86 | TRPM8 (0.58) | CTSLTACR1CTSBCTSSCTSK | |
| SCHEMBL5889247 | 0.86 | TRPM8 (0.58) | CTSLTACR1CTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202258-B2 | α- and β-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7037941-B2 | Alpha-and Beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050267214-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-12-01 | — | — | US | disclosed |
| EP-0813868-B1 | Retroviral protease inhibitors | MONSANTO CO (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20030158236-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2003-08-21 | — | — | US | disclosed |
| US-6444678-B1 | α- and β-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | G. D. SEARLE & CO. | 2002-09-03 | — | — | US | disclosed |
| US-6156768-A | Alpha- and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2000-12-05 | — | — | US | disclosed |
| EP-0731088-B1 | Retroviral protease inhibitors | MONSANTO CO (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-0558603-B1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO CO (US) | 1998-08-26 | — | — | EP | disclosed |
| EP-0666842-B1 | HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1998-06-24 | — | — | EP | disclosed |
| EP-0558603-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558630-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558657-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558673-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0554400-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-08-11 | — | — | EP | disclosed |
| WO-1992008700-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008701-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008698-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008688-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008699-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158236-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | ASPH, DNPEP, PEPD | ADORA3 3659/4885ADORA2A 3988/4885ADORA2B 3497/4885 |
| US-20050267214-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | ASPH, DNPEP, PEPD | ADORA3 3513/4885ADORA2A 3874/4885ADORA2B 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.